全文获取类型
收费全文 | 34770篇 |
免费 | 801篇 |
国内免费 | 65篇 |
专业分类
耳鼻咽喉 | 139篇 |
儿科学 | 2152篇 |
妇产科学 | 919篇 |
基础医学 | 1919篇 |
口腔科学 | 771篇 |
临床医学 | 2056篇 |
内科学 | 8309篇 |
皮肤病学 | 374篇 |
神经病学 | 1514篇 |
特种医学 | 933篇 |
外科学 | 6204篇 |
综合类 | 2562篇 |
预防医学 | 4976篇 |
眼科学 | 572篇 |
药学 | 1353篇 |
8篇 | |
中国医学 | 190篇 |
肿瘤学 | 685篇 |
出版年
2023年 | 186篇 |
2022年 | 376篇 |
2021年 | 710篇 |
2020年 | 500篇 |
2019年 | 4088篇 |
2018年 | 3123篇 |
2017年 | 1455篇 |
2016年 | 310篇 |
2015年 | 360篇 |
2014年 | 1130篇 |
2013年 | 870篇 |
2012年 | 899篇 |
2011年 | 947篇 |
2010年 | 815篇 |
2009年 | 672篇 |
2008年 | 585篇 |
2007年 | 583篇 |
2006年 | 461篇 |
2005年 | 408篇 |
2004年 | 356篇 |
2003年 | 290篇 |
2002年 | 214篇 |
2001年 | 208篇 |
2000年 | 166篇 |
1999年 | 155篇 |
1998年 | 130篇 |
1997年 | 148篇 |
1996年 | 76篇 |
1995年 | 53篇 |
1994年 | 42篇 |
1993年 | 26篇 |
1992年 | 25篇 |
1991年 | 22篇 |
1990年 | 17篇 |
1989年 | 20篇 |
1988年 | 15篇 |
1987年 | 11篇 |
1985年 | 1163篇 |
1984年 | 1759篇 |
1983年 | 1372篇 |
1982年 | 1408篇 |
1981年 | 1342篇 |
1980年 | 1209篇 |
1979年 | 1317篇 |
1978年 | 1182篇 |
1977年 | 787篇 |
1976年 | 1055篇 |
1975年 | 905篇 |
1974年 | 815篇 |
1973年 | 842篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
《Vaccine》2022,40(7):1001-1009
Vaccination guidelines for dogs and cats indicate that core vaccines (for dogs, rabies, distemper, adenovirus, parvovirus; for cats, feline parvovirus, herpes virus-1, calicivirus) are essential to maintain health, and that non-core vaccines be administered according to a clinician’s assessment of a pet’s risk of exposure and susceptibility to infection. A reliance on individual risk assessment introduces the potential for between-practice inconsistencies in non-core vaccine recommendations. A study was initiated to determine non-core vaccination rates of dogs (Leptospira, Borrelia burgdorferi, Bordetella bronchiseptica, canine influenza virus) and cats (feline leukemia virus) in patients current for core vaccines in veterinary practices across the United States. Transactional data for 5,531,866 dogs (1,670 practices) and 1,914,373 cats (1,661 practices) were retrieved from practice management systems for the period November 1, 2016 through January 1, 2020, deidentified and normalized. Non-core vaccination status was evaluated in 2,798,875 dogs and 788,772 cats that were core-vaccine current. Nationally, median clinic vaccination rates for dogs were highest for leptospirosis (70.5%) and B. bronchiseptica (68.7%), and much lower for canine influenza (4.8%). In Lyme-endemic states, the median clinic borreliosis vaccination rate was 51.8%. Feline leukemia median clinic vaccination rates were low for adult cats (34.6%) and for kittens and 1-year old cats (36.8%). Individual clinic vaccination rates ranged from 0 to 100% for leptospirosis, B. bronchiseptica and feline leukemia, 0–96% for canine influenza, and 0–94% for borreliosis. Wide variation in non-core vaccination rates between clinics in similar geographies indicates that factors other than disease risk are driving the use of non-core vaccines in pet dogs and cats, highlighting a need for veterinary practices to address gaps in patient protection. Failure to implement effective non-core vaccination strategies leaves susceptible dogs and cats unprotected against vaccine-preventable diseases. 相似文献
2.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
3.
Tonya J.H. White 《Journal of the American Academy of Child and Adolescent Psychiatry》2019,58(11):1042-1050
4.
5.
6.
7.
8.
9.
10.